Joysbio Covid-19 antigentest (1pcs)

17.00 £  Excl. VAT

447 in stock

SKU: COV-AG-1-NASAL Categories: ,

Covid-19 Antigen single test with nasal swab from Joysbio. 1 pcs per package.

In June 2020, JOYSBIO Biotechnology released a new COVID-19 Antigen Rapid Test Kit (colloidal gold). This coronavirus test kit is a lateral flow immunoassay for qualitative detection of SARS-COV-2 antigen (nucleoside protein) with upper respiratory tract samples taken with a nasal swab during the acute infection phase. The test is intended for professional use.

 

Properties

  • 15-minute analysis
  • Easy to use test with few simple steps
  • Works with nasal swab (included)
  • CE-IVD certified

 

Clinical features and accuracy

Joysbio’s test kit for Coronavirus Ag has been evaluated in two different clinical trials conducted in Italy and China. A total of 190 and 150 samples, respectively, were tested with Joysbio’s COVID-19 Antigen Rapid Test Kit. These samples were collected with a nasal swab, from patients 1-5 days after the onset of symptoms. The sensitivity and specificity of the coronavirus antigen test kit were compared with a CE-IVD-labeled / FDA EUA-approved RT-PCR test kit (BGI). This clinical evaluation was performed under the assumption that SARS-CoV is no longer spreading in society.

According to the clinical analysis of the 190 and 150 samples in comparison with RT-PCR samples, the results for 1-5 days from symptom onset are as follows:

  • Sensitivity 98,72%
  • Specificity 99,60%

 

The test measures the antigens that attach to the virus body and is designed for in vitro qualitative detection of SARS-CoV-2 neutrocapsid antigen in nasal (NS) swab samples directly from individuals suspected of being infected with COVID-19, within the first 5 days after the onset of symptoms.

The antigen is generally detectable in samples taken in the upper respiratory tract during the acute phase of infection. A positive test result indicates the presence of viral antigens, but the clinical correlation with the patient’s medical history and other diagnostic information is necessary to determine the infection status.

A negative outcome should be treated as presumptive, which does not exclude a SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. A negative result should be seen in the light of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and if necessary confirmed by a molecular analysis, for patient management.

 

What is the difference between Covid-19 RT-PCR test, Antigen test and Antibody test?

There are two types of tests available for COVID-19: viral test and antibody test. RT-PCR tests and antigen tests are both viral tests that detect the presence of SARS-CoV-2 from upper nasal samples. The RT-PCR test focuses on the genomic information (RNA) of the virus; however, the COVID-19 antigen test kit detects bits of proteins that make up the SARS-CoV-2 virus. The WHO recommends both RT-PCR tests and antigen tests for the diagnosis of active coronavirus infection.

For more information, read the English leaflet / instructions for use. Can be downloaded under the section documents.